Octarine Bio

The company's core technology platform focuses on engineering yeast to produce cannabinoids and psilocybin-derivatives for therapeutic applications, as well as other natural ingredients. This is achieved through advanced metabolic engineering, which modifies the yeast's genetic pathways to efficiently create these target molecules. In 2021, Octarine Bio secured a €2 million seed funding round led by Danish investors, including the Fermentation Gut Hub and a Vækstfonden-managed fund, to advance its technology and scale up production. A significant milestone was achieved in 2023 with the launch of a new R&D facility in Copenhagen, enabling the company to double its capacity. Earlier, in 2020, the company had received a grant of over €500,000 from the Bio-Based Industries Joint Undertaking (BBI JU) to develop a bio-based textile dyeing technology.

Octarine Bio operates on a business-to-business model, partnering with companies in the pharmaceutical, nutraceutical, and textile industries to provide them with sustainably produced ingredients. A key product in their pipeline is PurePalette™, a bio-based textile dye intended as a direct replacement for synthetic dyes derived from petroleum. This product aims to address the environmental pollution associated with the textile industry by offering a biodegradable and sustainable alternative. The company's technology allows for the production of a wide spectrum of colors through fermentation, offering a drop-in solution for textile manufacturers seeking to improve their environmental footprint.